Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics
Potential for Human Monoclonal Antibody COVID-19 Therapeutics to be Developed as a Result of the Collaboration.
today announced it has entered into a research collaboration and option agreement with Columbia University
The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine.
tonixpharma.com/news-events/press-releases/detail/1215/tonix-pharmaceuticals-announces-research-collaboration-to
alphastocknews.com/tonix-pharmaceuticals-tnxp-stock-rockets-on-covid-19-news/3791/
Dissecting the Immune Response to SARS-CoV-2 in Healthy Recovered or Asymptomatic Volunteers May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics
Potential for Human Monoclonal Antibody COVID-19 Therapeutics to be Developed as a Result of the Collaboration.
today announced it has entered into a research collaboration and option agreement with Columbia University
The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine.
tonixpharma.com/news-events/press-releases/detail/1215/tonix-pharmaceuticals-announces-research-collaboration-to
alphastocknews.com/tonix-pharmaceuticals-tnxp-stock-rockets-on-covid-19-news/3791/
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.